Lv3
350 积分 2022-12-16 加入
Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
5天前
已完结
Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
19天前
已完结
A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib in Patients with Myelofibrosis who were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single-Arm, Multicenter, Open-Label, Phase Ib Study
24天前
已关闭
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
1个月前
已完结
Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
4个月前
已完结
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
4个月前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
5个月前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
5个月前
已完结
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
5个月前
已完结
Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis
7个月前
已完结
皖公网安备34019202002308
